| Patent(s) and the Corresponding Patented Drug(s) |
Top |
| World Intellectual Property Organization (WIPO) |
| Patent ID |
WO2016089804 |
| Title |
Inhibitors of Ezh2. |
| Abstract |
The present invention relates to compounds that inhibit activity of the histone lysine N-methyltransferase, Enhancer of Zeste Homolog 2 (EZH2), pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, such as hematologic and solid tumors. |
| Applicant(s) |
Eli Lilly and Company |
| Representative Drug(s) |
D01PZZ |
Drug Info
|
IC50 = 1.43 nM |
Click to Show More |
[1] |
|
2
|
D0G1JR
|
Drug Info
|
IC50 = 14.8 nM
|
[1] |
| Patent ID |
WO2015193768 |
| Title |
Aryl Fused Lactams As Ezh2 Modulators. |
| Abstract |
This invention relates to compounds of Formula (I) in which R1, R2, R3, R4, X and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer. |
| Applicant(s) |
Pfizer Inc |
| Representative Drug(s) |
D0D4UH |
Drug Info
|
IC50 = 10 nM |
Click to Show More |
[1] |
|
2
|
D0M8AA
|
Drug Info
|
IC50 = 200000 nM
|
[1] |
| Patent ID |
WO2016102493 |
| Title |
Imidazopyridine Ezh2 Inhibitors. |
| Abstract |
The present invention relates to imidazopyridines of general formula (I), to a method for their preparation, to intermediates for their preparation, to pharmaceutical compositions comprising at least one of those compounds, and to the use thereof. |
| Applicant(s) |
Bayer Pharma Aktiengesellschaft the Broad Institute Inc |
| Representative Drug(s) |
D0M4LK |
Drug Info
|
IC50 = 76.1 nM |
[1] |
